Physicians at SSM Health Cardinal Glennon are using genetic profiling for individual treatment of leukemia for better response to a child’s specific case. Focusing on the whole child, the provider has embraced advanced clinical trials to offer children with leukemia the full benefit of advances in therapies.
Once example is the use of BLINCYTO (blinatumomab), a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy. Blinatumomab, an immunologic therapy, was first approved by the Food and Drug Administration (FDA) in 2014, reports Fox2 Now St. Louis.
SSM Health Cardinal Glennon Children’s Hospital now uses this therapy not only in both relapsed pre-B acute lymphoblastic leukemia (the most common childhood cancer), but in addition, in clinical trials in some select patients as an initial therapy. The study is managed through the Children’s Oncology Group, an international cooperative organization targeting the advancement of pediatric cancer treatment.
About SSM Health Cardinal Glennon
SSM Health Cardinal Glennon is a leading academic medical...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).